To Date Nouveau BioSciences has:

1. Developed a proprietary platform technology that can rapidly evaluate thousands of drug combinations for potential efficacy against selected cancer cells lines enabling us to discover and develop derisked new drug entities over a period of months - not years - hastening the time to clinical study.

2. Filed multiple patents protecting both platform technology and new drug entities.

3. Developed two new drug entities with superior efficacy over the standard of care, poised to enter the clinic.

4. Developed technologies to tag nanoparticle surfaces facilitating homing to specific tumor cells.

5. Developed technologies for integrating proven drugs and synergistic combinations of drugs into amphiphilic nanoparticles, a delivery system that has demonstrated dramatically higher therapeutic efficacy and lower toxicity.

6. Developed additional technologies to hone tag nanoparticle surfaces to bind more effectively with, and achieve greater efficacy against, specific tumor cells.

7. Opening a 100% Nouveau-owned Nanovations laboratory to generate new drug assets, with all IP to be held exclusively by Nouveau.